| Keywords: |
cancer survival; gene mutation; drug safety; liver function; antineoplastic agents; note; follow up; antineoplastic agent; imatinib; protein kinase inhibitor; protein targeting; qt prolongation; epidermal growth factor receptor; editorial; cytogenetics; dasatinib; chronic myeloid leukemia; pyrimidines; protein kinase inhibitors; patient care; cancer regression; drug antagonism; cancer relapse; pleura effusion; bcr abl protein; piperazines; nilotinib; piperazine derivative; pyrimidine derivative; thiazoles; b raf kinase; phosphotransferase inhibitor; fusion proteins, bcr-abl; muscle cramp; myeloid leukemia; 4 methyl n (3 (4 methylimidazol 1 yl) 5 (trifluoromethyl)phenyl) 3 ((4 pyridin 3 ylpyrimidin 2 yl)amino)benzamide; 4-methyl-n-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide; thiazole derivative; leukemia, myeloid, chronic-phase
|
